GSK2578215A
Chemical Name: 5-(2-Fluoro-4-pyridinyl)-2-(phenylmethoxy)-N-3-pyridinylbenzamide
Purity: ≥99%
Biological Activity
GSK2578215A is a potent LRRK2 inhibitor (IC50 values are 8.9 and 10.1 nM for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 over a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition.
Hockey L, Kilpatrick B, Eden E, Lin-Moshier Y, Brailoiu G, Brailoiu E, Futter C, Schapira A, Marchant J, Patel S
J Cell Sci, 2015;128(2):232-8. -
Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response
J Park, JW Lee, SC Cooper, HE Broxmeyer, JR Cannon, CH Kim
J. Leukoc. Biol., 2017;0(0):. -
GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substituent-N-arylbenzamide LRRK2 kinase inhibitor.
Reith et al.
Bioorg.Med.Chem.Lett., 2012;22:5625
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for GSK2578215A
The citations listed below are publications that use Tocris products. Selected citations for GSK2578215A include:
19 Citations: Showing 1 - 10
-
LRRK2 is required for CD38-mediated NAADP-Ca2+ signaling and the downstream activation of TFEB (transcription factor EB) in immune cells.
Authors: Chong-Shan Et al.
Autophagy 2022;18:204-222
-
LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss.
Authors: Sung-Woo Et al.
Cells 2022;11
-
The small molecule DIPQUO promotes osteogenic differentiation via inhibition of glycogen synthase kinase 3-beta signaling.
Authors: Shuibing Et al.
J Biol Chem 2021;296:100696
-
LRRK2 activation controls the repair of damaged endomembranes in macrophages.
Authors: Huw R Et al.
EMBO J 2020;39:e104494
-
Protein synthesis is suppressed in sporadic and familial Parkinson's disease by LRRK2.
Authors: Eleanor T Et al.
FASEB J 2020;34:14217-14233
-
Leucine-rich repeat kinase 2 phosphorylation on synapsin I regulates glutamate release at pre-synaptic sites.
Authors: Elisa Et al.
J Neurochem 2019;150:264-281
-
Brain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage.
Authors: Bae Et al.
Cell Death Dis 2018;9:1125
-
LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages.
Authors: Brian D Et al.
EMBO J 2018;37
-
LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
Authors: Ho Et al.
Cell Biochem Funct 2018;36:431
-
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4.
Authors: Russo Et al.
J Neuroinflammation 2018;15:297
-
RAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes Centrosomal Deficits via RAB8A.
Authors: Madero-Pérez Et al.
Front Mol Neurosci 2018;11
-
Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2dephosphorylation as a pharmacodynamic biomarker.
Authors: Perera Et al.
Scientific Reports 2016;6:31391
-
LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate.
Authors: Belluzzi Et al.
Mol Neurodegener 2016;11:1
-
Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
Authors: Ho Et al.
Mol Brain 2015;8:54
-
Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.
Authors: Justin Et al.
J Neurosci 2015;35:5271-83
-
Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.
Authors: Russo Et al.
Oncotarget 2015;12:230
-
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex.
Authors: Cirnaru Et al.
Front Mol Neurosci 2014;7:49
-
The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling.
Authors: Saez-Atienzar Et al.
Cell Death Dis. 2014;5:e1368
-
Inhibition of LRRK2 kinase activity stimulates macroautophagy.
Authors: Manzoni Et al.
Biochim Biophys Acta 2013;1833:2900
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for GSK2578215A
There are currently no reviews for this product. Be the first to review GSK2578215A and earn rewards!
Have you used GSK2578215A?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image